Trends in Antibiotic Resistance in Urologic Practice

European Urology Focus

Volumn 2, Issue 4, 2016, Pages 363-373

  Kandil, Hala ^a   Cramp, Emma ^b   Vaghela, Tejal ^a  

^a WEST HERTFORDSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Acute pyelonephritis; Antimicrobial resistance; Catheter associated urinary tract infection; Complicated urinary tract infection; Prostatitis; Transurethral prostate biopsy; Uncomplicated urinary tract infection; Urologic infections

Indexed keywords

AMINOPENICILLIN; CARBAPENEM DERIVATIVE; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN DERIVATIVE; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; NITROFURANTOIN; PIVMECILLINAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMOCILLIN; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIURIA; CATHETER INFECTION; CATHETERIZATION; DISEASE SEVERITY; ENTEROCOCCUS; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MORTALITY; NONHUMAN; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PROSTATE CARCINOMA; PROSTATITIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEPSIS; STAPHYLOCOCCUS; TRANSRECTAL ULTRASONOGRAPHY; TRANSRECTAL ULTRASOUND BIOPSY OF THE PROSTATE; TREND STUDY; URINARY TRACT INFECTION;

EID: 84995403737     PISSN: None     EISSN: 24054569     Source Type: Journal    
DOI: 10.1016/j.euf.2016.09.006     Document Type: Review

References (129)

1. [1] World Health Organization. The evolving threat of antimicrobial resistance: options for action. Geneva, Switzerland: WHO; 2012. http://apps.who.int/iris/bitstream/10665/44812/1/9789241503181_eng.pdf.
2. [2] Bjerklund Johansen, T.E., Cek, M., Naber, K., Stratchounski, L., Svendsen, M.V., Tenke, P., Prevalence of hospital-acquired urinary tract infections in urology departments. Eur Urol 51 (2007), 1100–1111, 10.1016/j.eururo.2006.08.012.
3. [3] Ronald, A.R., Nicolle, L.E., Stamm, E., et al. Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents 17 (2001), 343–348.
4. [4] Totsika, M., Moriel, D.G., Idris, A., et al. Uropathogenic Escherichia coli mediated urinary tract infection. Curr Drug Targets 13 (2012), 1386–1399.
5. [5] Stamm, W.E., Norrby, S.R., Urinary tract infections: disease panorama and challenges. J Infect Dis 183:Suppl (2001), S1–S4, 10.1086/318850.
6. [6] Zalmanovici Trestioreanu A, Green H, Paul M, Yaphe J, Leibovici L. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2010;:CD007182. http://dx.doi.org/10.1002/14651858.CD007182.pub2.
7. [7] Costelloe, C., Metcalfe, C., Lovering, A., Mant, D., Hay, A.D., Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. Br Med J, 340, 2010, c2096.
8. [8] Bilinski, P., Kapka-Skrzypczak, L., Posobkiewicz, M., Bondaryk, M., Holownia, P., Wojtyla, A., Public health hazards in Poland posed by foodstuffs contaminated with E. coli O104:H4 bacterium from the recent European outbreak. Ann Agric Environ Med 19 (2012), 3–10.
9. [9] von Baum, H., Marre, R., Antimicrobial resistance of Escherichia coli and therapeutic implications. Int J Med Microbiol 295 (2005), 503–511, 10.1016/j.ijmm.2005.07.002.
10. [10] van der Bij, A.K., Pitout, J.D.D., The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. J Antimicrob Chemother 67 (2012), 2090–2100, 10.1093/jac/dks214.
11. [11] Poirel, L., Bonnin, R.A., Nordmann, P., Genetic support and diversity of acquired extended-spectrum β-lactamases in Gram-negative rods. Infect Genet Evol 12 (2012), 883–893, 10.1016/j.meegid.2012.02.008.
12. [12] Bradford, P.A., Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14 (2001), 933–951, 10.1128/CMR.14.4.933-951.2001.
13. [13] Kliebe, C., Nies, B.A., Meyer, J.F., Tolxdorff-Neutzling, R.M., Wiedemann, B., Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 28 (1985), 302–307.
14. [14] Bush K, Palzkill T. β-Lactamase classification and amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant enzymes. Burlington, MA: Lahey Clinic; 2015. www.lahey.org/studies.
15. [15] Petty, N.K., Ben Zakour, N.L., Stanton-Cook, M., et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A. 111 (2014), 5694–5699, 10.1073/pnas.1322678111.
16. [16] European Centre for Disease Prevention and Control. Annual antimicrobial resistance surveillance reports 2010-2013. Stockholm, Sweden: ECDC; 2014. http://ecdc.europa.eu/en/publications/surveillance_reports/arhai/pages/annual-antimicrobial-resistance-surveillance-report.aspx.
17. [17] Queenan, A.M., Bush, K., Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 20 (2007), 440–458, 10.1128/CMR.00001-07.
18. [18] Canton, R., Akova, M., Carmeli, Y., et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18 (2012), 413–431, 10.1111/j.1469-0691.2012.03821.x.
19. [19] Shevchenko, O.V., Mudrak, D.Y., Skleenova, E.Y., et al. First detection of VIM-4 metallo-β-lactamase-producing Escherichia coli in Russia. Clin Microbiol Infect 18 (2012), E214–E217, 10.1111/j.1469-0691.2012.03827.x.
20. [20] Nordmann, P., Naas, T., Poirel, L., Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17 (2011), 1791–1798, 10.3201/eid1710.110655.
21. [21] Mushtaq, S., Irfan, S., Sarma, J.B., et al. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother 66 (2011), 2002–2005, 10.1093/jac/dkr226.
22. [22] Glasner, C., Albiger, B., Buist, G., et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 18:28 (2013), 1–7.
23. [23] Munoz-Price, L.S., Poirel, L., Bonomo, R.A., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13 (2013), 785–796, 10.1016/S1473-3099(13)70190-7.
24. [24] Wailan, A.M., Paterson, D.L., The spread and acquisition of NDM-1: a multifactorial problem. Expert Rev Anti Infect Ther 12 (2014), 91–115, 10.1586/14787210.2014.856756.
25. [25] Poirel, L., Potron, A., Nordmann, P., OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67 (2012), 1597–1606, 10.1093/jac/dks121.
26. [26] Peleg, A.Y., Hooper, D.C., Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362 (2010), 1804–1813, 10.1056/NEJMra0904124.
27. [27] Kaper, J.B., Nataro, J.P., Mobley, H.L., Pathogenic Escherichia coli. Nat Rev Microbiol 2 (2004), 123–140, 10.1038/nrmicro818.
28. [28] Johnson, T.J., Nolan, L.K., Pathogenomics of the virulence plasmids of Escherichia coli. Microbiol Mol Biol Rev 73 (2009), 750–774, 10.1128/MMBR.00015-09.
29. [29] Erb, A., Sturmer, T., Marre, R., Brenner, H., Prevalence of antibiotic resistance in Escherichia coli: overview of geographical, temporal, and methodological variations. Eur J Clin Microbiol Infect Dis 26 (2007), 83–90, 10.1007/s10096-006-0248-2.
30. [30] Hopkins, K.L., Davies, R.H., Threlfall, E.J., Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 25 (2005), 358–373, 10.1016/j.ijantimicag.2005.02.006.
31. [31] Hooper, D.C., Mechanisms of fluoroquinolone resistance. Drug Resist Updat 2 (1999), 38–55, 10.1054/drup.1998.0068.
32. [32] Ruiz, J., Pons, M.J., Gomes, C., Transferable mechanisms of quinolone resistance. Int J Antimicrob Agents 40 (2012), 196–203, 10.1016/j.ijantimicag.2012.02.011.
33. [33] Robicsek, A., Jacoby, G.A., Hooper, D.C., The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 6 (2006), 629–640, 10.1016/S1473-3099(06)70599-0.
34. [34] Walsh, F., Rogers, T.R., Comparison of plasmid-mediated quinolone resistance and extended-spectrum β-lactamases in third-generation cephalosporin-resistant enterobacteriaceae from four Irish hospitals. J Med Microbiol 61 (2012), 142–147, 10.1099/jmm.0.035246-0.
35. [35] Mugnaioli, C., Luzzaro, F., De Luca, F., et al. CTX-M-type extended-spectrum β-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother 50 (2006), 2700–2706, 10.1128/AAC.00068-06.
36. [36] Ewers, C., Bethe, A., Semmler, T., Guenther, S., Wieler, L.H., Extended-spectrum β-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective. Clin Microbiol Infect 18 (2012), 646–655, 10.1111/j.1469-0691.2012.03850.x.
37. [37] Schultsz, C., Geerlings, S., Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy. Drugs 72 (2012), 1–16, 10.2165/11597960-000000000-00000.
38. [38] Over, U., Gur, D., Unal, S., Miller, G.H., The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey. Clin Microbiol Infect 7 (2001), 470–478.
39. [39] Zarubica, T., Baker, M.R., Wright, H.T., Rife, J.P., The aminoglycoside resistance methyltransferases from the ArmA/Rmt family operate late in the 30S ribosomal biogenesis pathway. RNA 17 (2011), 346–355, 10.1261/rna.2314311.
40. [40] Lindemann, P.C., Risberg, K., Wiker, H.G., Mylvaganam, H., Aminoglycoside resistance in clinical Escherichia coli and Klebsiella pneumoniae isolates from Western Norway. APMIS 120 (2012), 495–502, 10.1111/j.1600-0463.2011.02856.x.
41. [41] Livermore, D.M., Mushtaq, S., Warner, M., et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66 (2011), 48–53, 10.1093/jac/dkq408.
42. [42] Galimand, M., Sabtcheva, S., Courvalin, P., Lambert, T., Worldwide disseminated armA aminoglycoside resistance methylase gene is borne by composite transposon Tn1548. Antimicrob Agents Chemother 49 (2005), 2949–2953, 10.1128/AAC.49.7.2949-2953.2005.
43. [43] Canton, R., Coque, T.M., The CTX-M β-lactamase pandemic. Curr Opin Microbiol 9 (2006), 466–475, 10.1016/j.mib.2006.08.011.
44. [44] Livermore, D.M., Canton, R., Gniadkowski, M., et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59 (2007), 165–174, 10.1093/jac/dkl483.
45. [45] Lopez-Cerero, L., Bellido, M., del, M., Serrano, L., et al. Escherichia coli O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. Enferm Infecc Microbiol Clin 31 (2013), 385–388, 10.1016/j.eimc.2012.09.005.
46. [46] Rogers, B.A., Sidjabat, H.E., Paterson, D.L., Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 66 (2011), 1–14, 10.1093/jac/dkq415.
47. [47] van Duijn, P.J., Dautzenberg, M.J.D., Oostdijk, E.A.N., Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care 17 (2011), 658–665, 10.1097/MCC.0b013e32834c9d87.
48. [48] Kronvall, G., Antimicrobial resistance 1979-2009 at Karolinska hospital, Sweden: normalized resistance interpretation during a 30-year follow-up on Staphylococcus aureus and Escherichia coli resistance development. APMIS 118 (2010), 621–639, 10.1111/j.1600-0463.2010.02660.x.
49. [49] European Centre for Disease Prevention and Control. Annual epidemiological report 2013. Reporting on 2011 surveillance data and 2012 epidemic intelligence data. 2013, ECDC, Stockhol, Sweden, 10.2900/13174.
50. [50] Thorsteinsdottir, T.R., Haraldsson, G., Fridriksdottir, V., Kristinsson, K.G., Gunnarsson, E., Prevalence and genetic relatedness of antimicrobial-resistant Escherichia coli isolated from animals, foods and humans in Iceland. Zoonoses Public Health 57 (2010), 189–196, 10.1111/j.1863-2378.2009.01256.x.
51. [51] Priamchuk, S.D., Fursova, N.K., Abaev, I.V., et al. [Genetic determinants of antibacterial resistance among nosocomial Escherichia coli, Klebsiella spp., and Enterobacter spp. isolates collected in Russia within 2003-2007]. Antibiot Khimioter 55 (2010), 3–10.
52. [52] European Antimicrobial Resistance Surveillance System. EARSS annual report 2008. Stockholm, Sweden: ECDC; 2009. http://ecdc.europa.eu/en/healthtopics/antimicrobial-resistance-and-consumption/antimicrobial_resistance/publications-documents/Documents/2008_EARSS_Annual_Report.pdf.
53. [53] Tonkic, M., Goic-Barisic, I., Punda-Polic, V., Prevalence and antimicrobial resistance of extended-spectrum β-lactamases-producing Escherichia coli and Klebsiella pneumoniae strains isolated in a university hospital in Split. Croatia. Int Microbiol 8 (2005), 119–124.
54. [54] Balode, A., Punda-Polic, V., Dowzicky, M.J., Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010. Int J Antimicrob Agents 41 (2013), 527–535, 10.1016/j.ijantimicag.2013.02.022.
55. [55] European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Stockholm, Sweden: ECDC; 2014. http://ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-europe-2014.pdf.
56. [56] Davies, J., Guy, R., Johnson, A.P., Sheridan, E.A., Hope, R.J., Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014. Euro Surveill 21:35 (2016), 1–9 http://www.eurosurveillance.org/images/dynamic/EE/V21N35/art22569.pdf.
57. [57] Maki, D.G., Tambyah, P.A., Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 7 (2001), 342–347, 10.3201/eid0702.700342.
58. [58] Grabe M, Bartoletti R, Johansen TEB, et al. Guidelines on urological infections. Arnhem, The Netherlands: European Association of Urology; 2015. http://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf.
59. [59] Gupta, K., Hooton, T.M., Naber, K.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52 (2011), 103–120, 10.1093/cid/ciq257.
60. [60] Kass, E.H., Schneiderman, L.J., Entry of bacteria into the urinary tracts of patients with inlying catheters. N Engl J Med 256 (1957), 556–557, 10.1056/NEJM195703212561206.
61. [61] Garibaldi, R.A., Burke, J.P., Britt, M.R., Miller, M.A., Smith, C.B., Meatal colonization and catheter-associated bacteriuria. N Engl J Med 303 (1980), 316–318, 10.1056/NEJM198008073030605.
62. [62] Garibaldi, R.A., Burke, J.P., Dickman, M.L., Smith, C.B., Factors predisposing to bacteriuria during indwelling urethral catheterization. N Engl J Med 291 (1974), 215–219, 10.1056/NEJM197408012910501.
63. [63] Nickel, J.C., Costerton, J.W., McLean, R.J., Olson, M., Bacterial biofilms: influence on the pathogenesis, diagnosis and treatment of urinary tract infections. J Antimicrob Chemother 33:Suppl A (1994), 31–41.
64. [64] Hooton, T.M., Bradley, S.F., Cardenas, D.D., et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis 50 (2010), 625–663.
65. [65] Warren, J.W., Platt, R., Thomas, R.J., Rosner, B., Kass, E.H., Antibiotic irrigation and catheter-associated urinary-tract infections. N Engl J Med 299 (1978), 570–573, 10.1056/NEJM197809142991103.
66. [66] Tambyah, P.A., Maki, D.G., Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch Intern Med 160 (2000), 678–682.
67. [67] Saint, S., Clinical and economic consequences of nosocomial catheter-related bacteriuria. Am J Infect Control 28 (2000), 68–75.
68. [68] Leuck, A.-M., Wright, D., Ellingson, L., Kraemer, L., Kuskowski, M.A., Johnson, J.R., Complications of Foley catheters — is infection the greatest risk?. J Urol 187 (2012), 1662–1666, 10.1016/j.juro.2011.12.113.
69. [69] Zarb, P., Coignard, B., Griskeviciene, J.B., et al. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill 17:46 (2012), 1–16 www.eurosurveillance.org/images/dynamic/EE/V17N46/art20316.pdf.
70. [70] Stark, R.P., Maki, D.G., Bacteriuria in the catheterized patient. What quantitative level of bacteriuria is relevant?. N Engl J Med 311 (1984), 560–564, 10.1056/NEJM198408303110903.
71. [71] Morton, S.C., Shekelle, P.G., Adams, J.L., et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil 83 (2002), 129–138.
72. [72] Bursle, E.C., Dyer, J., Looke, D.F.M., McDougall, D.A.J., Paterson, D.L., Playford, E.G., Risk factors for urinary catheter associated bloodstream infection. J Infect 70 (2015), 585–591, 10.1016/j.jinf.2015.01.001.
73. [73] American Cancer Society. Prostate cancer prevention and early detection. Atlanta, GA: ACS; 2009. www.cancer.org/cancer/prostatecancer/moreinformation/prostatecancerearlydetection/prostate-cancer-early-detection-acs-recommendations.
74. [74] Crawford, E.D., Haynes, A.L.J., Story, M.W., Borden, T.A., Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol 127 (1982), 449–451.
75. [75] Aron, M., Rajeev, T.P., Gupta, N.P., Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 85 (2000), 682–685.
76. [76] Williamson, D.A., Roberts, S.A., Paterson, D.L., et al. Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 54 (2012), 1406–1412, 10.1093/cid/cis194.
77. [77] Loeb, S., Carter, H.B., Berndt, S.I., Ricker, W., Schaeffer, E.M., Complications after prostate biopsy: data from SEER-Medicare. J Urol 186 (2011), 1830–1834, 10.1016/j.juro.2011.06.057.
78. [78] Heidenreich, A., Aus, G., Bolla, M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008), 68–80, 10.1016/j.eururo.2007.09.002.
79. [79] Raaijmakers, R., Kirkels, W.J., Roobol, M.J., Wildhagen, M.F., Schrder, F.H., Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 60 (2002), 826–830.
80. [80] Otrock, Z.K., Oghlakian, G.O., Salamoun, M.M., Haddad, M., Bizri, A.R.N., Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon. Infect Control Hosp Epidemiol 25 (2004), 873–877, 10.1086/502312.
81. [81] Zaytoun, O.M., Vargo, E.H., Rajan, R., Berglund, R., Gordon, S., Jones, J.S., Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 77 (2011), 1035–1041, 10.1016/j.urology.2010.12.067.
82. [82] Nam, R.K., Saskin, R., Lee, Y., et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183 (2010), 963–968, 10.1016/j.juro.2009.11.043.
83. [83] Loeb, S., van den Heuvel, S., Zhu, X., Bangma, C.H., Schroder, F.H., Roobol, M.J., Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 61 (2012), 1110–1114, 10.1016/j.eururo.2011.12.058.
84. [84] Loeb, S., Vellekoop, A., Ahmed, H.U., et al. Systematic review of complications of prostate biopsy. Eur Urol 64 (2013), 876–892, 10.1016/j.eururo.2013.05.049.
85. [85] Roberts, M.J., Parambi, A., Barrett, L., et al. Multifocal abscesses due to multiresistant Escherichia coli after transrectal ultrasound-guided prostate biopsy. Med J Aust 198 (2013), 282–284, 10.5694/mja12.11719.
86. [86] Wagenlehner, F.M.E., Pilatz, A., Waliszewski, P., Weidner, W., Johansen, T.E.B., Reducing infection rates after prostate biopsy. Nat Rev Urol 11 (2014), 80–86, 10.1038/nrurol.2013.322.
87. [87] Duplessis, C.A., Bavaro, M., Simons, M.P., et al. Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 79 (2012), 556–561, 10.1016/j.urology.2011.09.057.
88. [88] Liss, M.A., Peterson, E.M., Johnston, B., Osann, K., Johnson, J.R., Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy. Urology 81 (2013), 548–555, 10.1016/j.urology.2012.10.056.
89. [89] Pitout, J.D.D., Infections with extended-spectrum β-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 70 (2010), 313–333, 10.2165/11533040-000000000-00000.
90. [90] Williamson, D.A., Masters, J., Freeman, J., Roberts, S., Travel-associated extended-spectrum β-lactamase-producing Escherichia coli bloodstream infection following transrectal ultrasound-guided prostate biopsy. BJU Int 109 (2012), E21–E22, 10.1111/j.1464-410X.2012.11001.x.
91. [91] Steensels, D., Slabbaert, K., De Wever, L., Vermeersch, P., Van Poppel, H., Verhaegen, J., Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy — should we reassess our practices for antibiotic prophylaxis?. Clin Microbiol Infect 18 (2012), 575–581, 10.1111/j.1469-0691.2011.03638.x.
92. [92] Patel, U., Dasgupta, P., Amoroso, P., Challacombe, B., Pilcher, J., Kirby, R., Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int 109 (2012), 1781–1785, 10.1111/j.1464-410X.2011.10561.x.
93. [93] Cassier, P., Lallechere, S., Aho, S., et al. Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital. Clin Microbiol Infect 17 (2011), 1746–1751, 10.1111/j.1469-0691.2010.03349.x.
94. [94] Lifshitz, E., Kramer, L., Outpatient urine culture: does collection technique matter?. Arch Intern Med 160 (2000), 2537–2540.
95. [95] Fihn, S.D., Clinical, practice., Acute uncomplicated urinary tract infection in women. N Engl J Med 349 (2003), 259–266, 10.1056/NEJMcp030027.
96. [96] Foxman, B., Brown, P., Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 17 (2003), 227–241.
97. [97] Badalato G, Kaufmann M. Adult UTI. Linthicum, MD: American Urological Association; 2016. www.auanet.org/education/adult-uti.cfm.
98. [98] Vance-Bryan, K., Guay, D.R., Rotschafer, J.C., Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 19 (1990), 434–461, 10.2165/00003088-199019060-00003.
99. [99] Goto, T., Makinose, S., Ohi, Y., et al. Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol 5 (1998), 243–246.
100. [100] Batura, D., Rao, G.G., Bo Nielsen, P., Charlett, A., Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int 107 (2011), 760–764, 10.1111/j.1464-410X.2010.09715.x.
101. [101] Gopal Rao, G., Batura, D., Emergency hospital admissions attributable to infective complications of prostate biopsy despite appropriate prophylaxis: need for additional infection prevention strategies?. Int Urol Nephrol 46 (2014), 309–315, 10.1007/s11255-013-0529-5.
102. [102] Losco, G., Studd, R., Blackmore, T., Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate. BJU Int 113:Suppl (2014), 69–72, 10.1111/bju.12590.
103. [103] Shakil, J., Piracha, N., Prasad, N., et al. Use of outpatient parenteral antimicrobial therapy for transrectal ultrasound-guided prostate biopsy prophylaxis in the setting of community-associated multidrug-resistant Escherichia coli rectal colonization. Urology 83 (2014), 710–713, 10.1016/j.urology.2013.12.039.
104. [104] Taylor, A.K., Zembower, T.R., Nadler, R.B., et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 187 (2012), 1275–1279, 10.1016/j.juro.2011.11.115.
105. [105] Suwantarat, N., Dumford, D.M. 3rd, Ponce-Terashima, R., et al. Modification of antimicrobial prophylaxis based on rectal culture results to prevent fluoroquinolone-resistant Escherichia coli infections after prostate biopsy. Infect Control Hosp Epidemiol 34 (2013), 973–976, 10.1086/671734.
106. [106] Overduin, C.G., Futterer, J.J., Barentsz, J.O., MRI-guided biopsy for prostate cancer detection: a systematic review of current clinical results. Curr Urol Rep 14 (2013), 209–213, 10.1007/s11934-013-0323-z.
107. [107] Matagne, A., Ghuysen, M.F., Frère, J.M., Interactions between active-site-serine β-lactamases and mechanism-based inactivators: a kinetic study and an overview. Biochem J. 295 (1993), 705–711 www.ncbi.nlm.nih.gov/pmc/articles/PMC1134617.
108. [108] Rodriguez-Villalobos, H., Malaviolle, V., Frankard, J., de Mendonca, R., Nonhoff, C., Struelens, M.J., In vitro activity of temocillin against extended spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 57 (2006), 771–774, 10.1093/jac/dkl046.
109. [109] Glupczynski, Y., Huang, T.-D., Berhin, C., et al. In vitro activity of temocillin against prevalent extended-spectrum β-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 26 (2007), 777–783, 10.1007/s10096-007-0370-9.
110. [110] Livermore, D.M., Hope, R., Fagan, E.J., Warner, M., Woodford, N., Potz, N., Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 57 (2006), 1012–1014, 10.1093/jac/dkl043.
111. [111] Spencer, R.C., Temocillin. J Antimicrob Chemother 26 (1990), 735–737.
112. [112] Andrews, J.M., BSAC standardized disc susceptibility testing method (version 7). J Antimicrob Chemother 62 (2008), 256–278, 10.1093/jac/dkn194.
113. [113] Balakrishnan, I., Awad-El-Kariem, F.M., Aali, A., et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 66 (2011), 2628–2631, 10.1093/jac/dkr317.
114. [114] Mittermayer, H.W., Influence of temocillin on human bowel flora. Drugs 29 (1985), 43–48, 10.2165/00003495-198500295-00010.
115. [115] Kahlmeter, G., An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS project. J Antimicrob Chemother 51 (2003), 69–76.
116. [116] Ode, B., Haidl, S., Hoffstedt, B., Walder, M., Ursing, J., Fosfomycin versus ampicillin in the treatment of acute pyelonephritis. Chemioterapia 7 (1988), 96–100.
117. [117] Marchese, A., Gualco, L., Debbia, E.A., Schito, G.C., Schito, A.M., In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 22:Suppl 2 (2003), 53–59.
118. [118] Takahashi, K., Kanno, H., Synergistic activities of combinations of β-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 26 (1984), 789–791.
119. [119] Rodriguez-Bano, J., Alcala, J.C., Cisneros, J.M., et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med 168 (2008), 1897–1902, 10.1001/archinte.168.17.1897.
120. [120] Falagas, M.E., Kastoris, A.C., Kapaskelis, A.M., Karageorgopoulos, D.E., Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 10 (2010), 43–50, 10.1016/S1473-3099(09)70325-1.
121. [121] Kumon, H., Management of biofilm infections in the urinary tract. World J Surg. 24 (2000), 1193–1196, 10.1007/s002680010203.
122. [122] Dewar, S., Reed, L.C., Koerner, R.J., Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother 69 (2014), 303–308, 10.1093/jac/dkt368.
123. [123] Sougakoff, W., Jarlier, V., Comparative potency of mecillinam and other β-lactam antibiotics against Escherichia coli strains producing different β-lactamases. J Antimicrob Chemother 46:Suppl 1 (2000), 5–9.
124. [124] Bémer-Melchior, P., Gilly, L., Jugroot-Klotz, K., Brun, T., Névot, P., Paul, G., [Resistance to amoxicillin and amoxicillin-clavulanic acid combination of 231 clinical strains of Escherichia coli, isolated in 1992 at the Cochin Hospital]. Pathol Biol 43 (1995), 760–765 http://europepmc.org/abstract/MED/8746097.
125. [125] Marrs, E.C.L., Day, K.M., Perry, J.D., In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase. J Antimicrob Chemother 69 (2014), 2873–2875, 10.1093/jac/dku204.
126. [126] Nicolle, L.E., Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother 46:Suppl A (2000), 35–39.
127. [127] Merck Sharp & Dohme. Zerbaxa 1 g/0.5 g powder for concentrate for solution for infusion — summary of product characteristics. Electronic Medicines Compendium; 2015. www.medicines.org.uk/emc/medicine/31132.
128. [128] Committee for Medicinal Products for Human Use. Zerbaxa: CHMP assessment report. London, UK: EMA; 2011. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003772/WC500194598.pdf.
129. [129] Wagenlehner, F.M., Umeh, O., Steenbergen, J., Yuan, G., Darouiche, R.O., Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385 (2015), 1949–1956, 10.1016/S0140-6736(14)62220-0.